SCHEMBL6432336

SCHEMBL6432336

CC(C)(C)OC(=O)Nc1ccccc1Nc1nc2nonc2nc1N(N)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
TP53 P04637 2/20 0.37
MAPT P10636 2/20 0.37
CDKN1A P38936 1/20 0.37
SIRT1 Q96EB6 1/20 0.36
RXFP1 Q9HBX9 1/20 0.35
METAP1 P53582 1/20 0.35
LMNA P02545 3/20 0.34
POLB P06746 2/20 0.34
GAA P10253 1/20 0.34
RECQL P46063 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
BRD4 O60885 2/20 0.34
BRD9 Q9H8M2 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
P2RX7 Q99572 1/20 0.33
MAPK1 P28482 1/20 0.32
ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6439454 0.84 GAA (0.45) SMN1; SMN2TP53MAPTCDKN1ALMNA
SCHEMBL6416039 0.80 MEN1 (0.44) SMN1; SMN2TP53MAPTCDKN1ARXFP1
SCHEMBL6431994 0.78 GAA (0.46) SMN1; SMN2TP53MAPTCDKN1ALMNA
SCHEMBL6436802 0.77 MAPT (0.44) SMN1; SMN2TP53MAPTCDKN1APOLB
SCHEMBL6435667 0.76 MAPT (0.42) SMN1; SMN2TP53MAPTCDKN1ALMNA
SCHEMBL8191790 0.72 LMNA (0.45) RXFP1METAP1LMNAPOLBGAA
SCHEMBL6435103 0.72 HTT (0.33) LMNAPOLBKMT2AALDH1A1HTT
SCHEMBL6435528 0.70 HTT (0.32) HTT
SCHEMBL2880191 0.69 LMNA (0.54) SMN1; SMN2RXFP1METAP1LMNAPOLB
SCHEMBL13300748 0.66 STK17B (0.54) P2RX7MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed